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Case Report 
Severe Uterine Bleeding
Introduction 
Apgar et al. (2007) defined Menorrhagia as menstrual blood 
loss of C80 mL per cycle [1]. The current recommendation 
is to replace the term ‘menorrhagia’ by ‘heavy menstrual 
bleeding’ (HMB), as the former term is confusing with Latin and 
Greek roots which are loosely defined in the English medical 
language. In addition, the 80-mL criterion is of limited clinical 
prognostic value. HMB is a universal health problem affecting 
up to 30% of women in reproductive age and negatively 
impacting their physical activities and health-related quality 
of life. The National Institute for Clinical Excellence in the UK 
defines HMB as ‘‘excessive menstrual blood loss that interferes 
with the woman’s physical, emotional, social, and/or material 
quality of life’’. Idiopathic HMB is regular heavy bleeding in the 
absence of recognizable pelvic pathology or a general bleeding 
disorder. Fibroids have been found in up to 40% of women 
with HMB; however, half of all women having a hysterectomy 
for HMB are found to have a normal uterus . There are data 
suggesting that unrestrained local inflammatory events and/
or deficient repair processes within the endometrium may 
contribute to the onset of HMB Accordingly, medical therapy, 
e.g., non-steroidal anti-inflammatory drugs, antifibrinolytics, 
oral contraceptive pills, progestogens and other hormones, 
and levonorgestrel-releasing intrauterine system represents 
an attractive option to avoid unnecessary surgery (e.g., uterine 
ablation and hysterectomy).
Stemler (2004) states that menorrhagia is a common condition. 
Approximately 5% of females seek medical attention for it [2]. 
Menorrhagia is defined as cyclic menstrual bleeding producing 
more than 80 mL of blood and/or bleeding for more than seven 
consecutive days. Most individuals cannot accurately quantify 
the amount of menstrual bleeding in milliliters. Therefore, it is 
often helpful to ask the patient how the menses is disrupting her 
lifestyle. Most women have a consistent pattern of menstrual 
bleeding from month to month. When an excessive amount of 
bleeding is present during the expected menstrual cycle, an 
underlying organic or hematologic etiology must be considered. 
Since the definition of heavy menstrual bleeding varies, it is 
important to have guidelines for it. A normal menstrual pattern 
occurs every 21 to 35 days and lasts from two to seven days. 
Women lose approximately 30 to 40 cc of blood each cycle, 
which represents eight soaked pads or tampons per menses.
Byams (2007) defines menorrhagia or excessive menstrual 
bleeding as a common clinical problem that affects 8–10% 
of women of reproductive age [3]. Because menorrhagia has 
many physical causes, including uterine fibroids, endometriosis, 
thyroid problems, and cancer, physicians traditionally focus 
on the organic pathology of the uterus. However, one study 
showed that a cause for menorrhagia is never identified in 
approximately 50% of cases.3 The results of recent studies 
indicate that between 5% and 24% of women with menorrhagia 
may have undiagnosed von Willebrand disease (VWD), and as 
many as 2 million women in the United States may have either 
VWD or another type of bleeding disorder without knowing 
it. VWD is the most common bleeding disorder, affecting just 
over 1% of the general population. It is caused by a deficiency 
in the body’s ability to make a protein, von Willebrand factor, 
which localizes platelets to the site of bleeding and helps blood 
clot. Although VWD occurs with equal frequency among men 
and women, women are more likely to experience symptoms 
of VWD because of the increased bleeding it causes during 
their menstrual periods, during pregnancy, and after childbirth. 
Women with menorrhagia or VWD or both are at an increased 
risk for pain during menstruation, anemia, hospitalizations, 
blood transfusions, limitations in daily activities, time lost 
from work or school, adverse psychosocial effects, and a 
reduced quality of life (QOL). The results of a recent study 
showed that women with VWD reported poorer health-related 
QOL than women in the general population.6 Women with 
menorrhagia often undergo unnecessary surgical interventions 
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to relieve heavy menstrual bleeding. At least 60% of women 
with uncontrolled menorrhagia undergo hysterectomies or 
other surgical procedures, including endometrial ablation and 
dilation and curettage. With proper diagnoses, many women 
with bleeding disorders could avoid these complications and 
surgeries, decrease their level of menstrual bleeding, and 
improve their QOL. The Division of Blood Disorders (DBD) at the 
Centers for Disease Control and Prevention (CDC) has worked to 
assess physicians’ awareness of bleeding disorders, determine 
the prevalence of bleeding disorders among women, and 
evaluate the options for treating women with these disorders. 
Descriptions of some of the DBD’s activities within their Women 
with Bleeding Disorders program follow (Table 1)
Differential Diagnosis
anticoagulants, nonsteroidal antiinflammatory Infection: chlamydia/gonorrhea/Incomplete abortion
contraceptive, acetylsalicylic acid, Trauma/sexual abuse
sepsis, leukemia, aplastic anemia, Trichomonas
thrombocytopenia, idiopathic Pregnancy/ectopic pregnancy/
Willebrand disease, liver disease, Trophoblastic disease/spontaneous
polycystic ovarian syndrome Trauma/sexual abuse
Foreign body
Medication induced:
Treatment
For AZ, desmopressin acetate (DDAVP) nasal spray (Stimate) was 
chosen to help control her menorrhagia. Desmopressin acetate 
is the treatment of choice for vWD Type 1.13,36 Desmopressin 
may be given intravenously or intranasally, but the intranasal 
spray is equally efficacious and more convenient.36 Patients 
should also use desmopressin acetate prophylactically before 
minor outpatient gynecological surgeries, as well as for other 
mucosal or dental procedures. Desmopressin acetate promotes 
the release of normal functioning vWF from the blood vessel’s 
endothelial cell lining. It strengthens hemostasis by decreasing 
the bleeding time and increasing the levels of factor VIII and 
the (Abu, 2013) [4] .
Frazer et al., 2011, stated that both surgical and medical 
interventions are available for the treatment of heavy menstrual 
bleeding [5]. Treatments include the levonorgestrel-releasing 
intrauterine system (LNG-IUS), tranexamic acid, non-steroidal 
anti-inflammatory drugs, danazol, cyclical progestogens, and 
combined oral contraceptives (COCs). With the exception 
of the LNG-IUS, cyclical progestogens, and tranexamic acid, 
most medical treatments are prescribed off-label and without 
perspective, well-designed studies that validate or quantify 
their effect. Although COCs are used widely off-label for the 
treatment of heavy or prolonged menstrual bleeding, prior 
to 2009, no large-scale objective, randomised or placebo-
controlled data existed in the literature to support their 
use for this purpose 6, with only one small randomised trial 
reported. Surgical procedures, such as hysterectomy and 
endometrial ablation, offer effective strategies, but their cost 
and associated morbidity should limit these approaches to 
patients with whom medical therapies have failed. A novel 
and effective oral contraceptive containing estradiol valerate 
and dienogest (E 2V/DNG) have been shown to be associated 
with good cycle control and a good tolerability profile. This 
oral contraceptive has been available since May 2009 in many 
countries worldwide under the trade names Qlaira ® or Natazia 
TM. Recently, two identically designed Phase III trials, one 
conducted in Europe and Australia and the other in North 
America, were undertaken to evaluate the efficacy and safety 
of E 2V/DNG in the treatment of heavy and/or prolonged 
menstrual bleeding. This paper details the reduction in MBL and 
safety findings as well as the patients’ and investigators’ rating 
of the improvement in bleeding symptoms from an analysis of 
pooled data from these two Phase III clinical trials. By pooling 
data from the available studies, we sought to better define 
the decrease in MBL achieved with E 2V/DNG and its safety 
profile across a larger and more diverse population of women. 
A pooled analysis of these trials was judged to be appropriate 
because of their identical design and enrollment criteria.
Patient Education
After AZ’s condition was diagnosed, her NP made sure she was 
thoroughly educated about vWD. She was instructed to report 
any breakthrough bleeding or irregular menses. Women with 
vWD have heavier menses. If menstrual bleeding occurs at other 
times, then another source must be ruled out. AZ was instructed 
to report headaches, muscle weakness, nausea, vomiting, 
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and seizures because these can be signs of hyponatremia. 
The patient must avoid aspirin as well as nonsteroidal anti-
inflammatory drugs due to the risk of further defects in platelet 
function. AZ was instructed to inform all providers of her new 
diagnosis of vWD, especially before surgical procedures to the 
mucous membranes (mouth, nose, and throat). The patient 
should be taught the important factors to consider, which 
include her age, whether her family is complete, contraceptive 
requirements, the severity of her symptoms, and the patient’s 
culture and beliefs. Troublesome periods are a common 
problem, and nurses are likely to encounter women with them 
during the course of their practice, irrespective of whether 
they work in women’s health or gynecology. It is important to 
encourage women to describe their symptoms by establishing 
an open, accepting relationship, taking time, and asking the 
correct questions. It is also important for nurses to have a clear 
understanding of the normal menstrual function and blood 
clotting so that they can identify possible abnormalities that 
merit further investigation. Today much more can be done to 
relieve the symptoms of menorrhagia. Women do not need to 
endure heavy, painful bleeding, and they may need sympathetic 
support to encourage them to access what is available and 
select the best treatment to suit their particular circumstances 
(Gould, 2007) [6].
Implications for practice
These findings suggest that more effort may have to be made by 
the GP to understand the woman’s concerns and expectations 
regarding her menstrual symptoms and to explain the nature of 
bodily functions and likely causes of these symptoms. Women 
must be able to feel first that they have been listened to and 
then diagnosed so that treatment options can then be properly 
discussed, and a shared management decision reached. 
Menorrhagia may be seen to represent an exemplary of other 
problems that also cannot be objectively diagnosed, such as 
irritable bowel syndrome and chronic lower back pain that is 
presented in primary care and which GPs may be insufficiently 
skilled in managing. The place for a decision aid to assist both 
the GP and the woman with menorrhagia needs careful but 
urgent evaluation.
Directions of Future Research
Although researchers have made much progress in establishing 
the prevalence of bleeding disorders among women and 
evaluating the management options available to them and their 
physicians, DBD remains committed to expanding research 
in the area of women with bleeding disorders. DBD and its 
partners are currently developing a surveillance instrument 
to assess the prevalence of various problems among women 
and girls with diagnosed bleeding disorders who are receiving 
care at a network of federally funded hemophilia treatment 
centers (HTCs). HTCs were originally created to treat males 
with hemophilia; however, the number of females with 
bleeding problems seeking care at these centers has increased 
steadily over the last 10 years from 4800 to almost 9000. The 
main purpose of this data collection is to better characterize 
reproductive and other symptoms among women with blood 
disorders over time. DBD will also collect data on diagnoses, 
treatments, HTC referral patterns, and study participants’ 
QOL. Although menorrhagia is highly prevalent among women 
with bleeding disorders, it is not the only gynecological 
manifestation of these conditions: bleeding disorders have 
also been associated with an increased risk for ovarian 
cysts, endometriosis, fibroids, miscarriage, bleeding during 
pregnancy, and postpartum hemorrhage. However, because 
few prospective, casecontrol studies have compared the 
prevalence of these conditions among women with bleeding 
disorders with the prevalence among controls, a causal 
relationship has not been established. DBD plans to expand its 
research in order to elucidate the association between bleeding 
disorders and women’s risks for various adverse obstetrical 
and gynecological outcomes. The ultimate goals of the DBD 
Women with Bleeding Disorders program are to improve 
women’s QOL through the recognition, proper diagnosis, 
and management of bleeding disorders, reduce unnecessary 
surgical procedures among women with these disorders, and 
contribute to the development of a national protocol for the 
diagnosis, treatment, and management of bleeding disorders 
among women. Through the current and future activities 
described here, the program is making substantial progress 
toward meeting these goals as well as in supporting its mission 
to prevent and reduce morbidity associated with bleeding 
disorders among women (Hurskainen et al., 2004) [7-10].
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